Last reviewed · How we verify

tirofiban intravenous bolus plus infusion

Kosuyolu Heart Hospital · Phase 3 active Small molecule

tirofiban intravenous bolus plus infusion is a Small molecule drug developed by Kosuyolu Heart Hospital. It is currently in Phase 3 development. Also known as: Aggrastat.

At a glance

Generic nametirofiban intravenous bolus plus infusion
Also known asAggrastat
SponsorKosuyolu Heart Hospital
ModalitySmall molecule
PhasePhase 3

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about tirofiban intravenous bolus plus infusion

What is tirofiban intravenous bolus plus infusion?

tirofiban intravenous bolus plus infusion is a Small molecule drug developed by Kosuyolu Heart Hospital.

Who makes tirofiban intravenous bolus plus infusion?

tirofiban intravenous bolus plus infusion is developed by Kosuyolu Heart Hospital (see full Kosuyolu Heart Hospital pipeline at /company/kosuyolu-heart-hospital).

Is tirofiban intravenous bolus plus infusion also known as anything else?

tirofiban intravenous bolus plus infusion is also known as Aggrastat.

What development phase is tirofiban intravenous bolus plus infusion in?

tirofiban intravenous bolus plus infusion is in Phase 3.

Related